ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: L09 • ACR Convergence 2024

    Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis

    Hermine Brunner1, Caifeng Li2, Kogie Chinniah3, Yosef Uziel4, Olga Synoverska5, Sujata Sawhney6, Inmaculada Calvo Penades7, Ingrid Clara Louw8, Meiping Lu9, Pooja Nikunj Patel10, Pamela F. Weiss11, Cheng Chang12, Ivana Vranic13, Shixue Liu14, Annette Diehl15, Jose L. Rivas16, Carol A. Connell17, Gary G. Koch18, Alberto Martini19, Daniel J. Lovell1, Nicolino Ruperto20 and the PRINTO and PRCSG investigators, 1Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, 2Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, 3Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, 4Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, 5Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, 6Sir Ganga Ram Hospital, New Delhi, India, 7Hospital Universitario y Politécnico La Fe, Valencia, Spain, 8Panorama Medical Centre, Cape Town, South Africa, 9Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, 10Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, 11Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 12Pfizer Inc, New York, NY, 13Pfizer Ltd, Tadworth, United Kingdom, 14Pfizer Inc, Shanghai, China, 15Pfizer Inc, Collegeville, PA, 16Pfizer SLU, Madrid, Spain, 17Pfizer Inc, Groton, CT, 18University of North Carolina at Chapel Hill, Chapel Hill, NC, 19University of Genoa, Genoa, Italy, 20Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy

    Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…
  • Abstract Number: 0398 • ACR Convergence 2024

    Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data

    Mary Eckert1, Eveline Wu2, Melissa Oliver3, Joshua Scheck4, Sivia Lapidus5, Ummusen Kaya Akca6, Shima Yasin7, Aleksander Lenert8, Sara Stern9, Antonella insalaco10, Manuela Pardeo10, Gabriele Simonini11, Edoardo Marrani12, Xing Wang13, Bin Huang14, Leonard Kovalick15, Natalie Rosenwasser16, Erin Balay-Dustrude17, Gabriel Casselman16, Liau Adriel18, Ava Klein18, Yurong Shao4, Claire Yang4, Molly Briggs4, Emily Deng4, Iris Hamilton4, Ethan Mueller16, Elise Machrone4, Paige Trunnel4, Doaa Mosa19, Lori Tucker20, Hermann Girschick21, Ronald Laxer22, Georgina Tiller23, Jonathan Akikusa24, Christian Hedrich25, Karen Onel26, Fatma Dedeoglu27, Marinka Twilt28, Seza Ozen29, Polly Ferguson30, Laura Schanberg31, Bryce Reeve32 and Yongdong (Dan) Zhao33, 1Seattle Children's, Mercer Island, WA, 2University of North Carolina School of Medicine, Chapel Hill, NC, 3Indiana University, Indianapolis, IN, 4Seattle Children's Hospital, Seattle, 5Hackensack University Medical Center, Montclair, NJ, 6Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 7University of Iowa Carver College of Medicine, Abu Dhabi, United Arab Emirates, 8University of Iowa, Iowa City, IA, 9University of Utah, Salt Lake City, UT, 10IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 11Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 12University of Florence, Firenze, Florence, Italy, 13Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, 14Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, 15UNC Health Care, Durham, NC, 16Seattle Children's Hospital, Seattle, WA, 17University of Washington, Seattle, WA, 18Seattle Children’s Research Institute, University of Washington, Seattle, 19Mansoura University Hospital, Mansoura City, Egypt, 20BC Children's Hospital, Vancouver, BC, Canada, 21Vivantes Clinic Friedrichshain, Wuerzburg, Germany, 22SickKids, Toronto, ON, Canada, 23University of British Columbia - Vancouver, Vancouver, BC, Canada, 24Royal Children's Hospital, Parkville, Victoria, Australia, 25University of Liverpool, Liverpool, United Kingdom, 26HSS, New York, NY, 27Boston Children's Hospital, Boston, MA, 28Alberta Children's Hospital, Calgary, AB, Canada, 29Department of Pediatrics, Hacettepe University, Ankara, Turkey, 30University of Iowa Carver College of Medicine, Iowa City, IA, 31Duke University Medical Center, DURHAM, NC, 32Duke University School of Medicine, Durham, 33University of Washington, Redmond, WA

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…
  • Abstract Number: 0557 • ACR Convergence 2024

    What Factors Are Associated with Pain Intensity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)

    Marco Garrido-Cumbrera1, Victoria Navarro Compán2, Fernando Andres Sommerfleck3, Christine Bundy4, Souzi Makri5, José Correa-Fernández6, Shashank Akerkar7, Jo Lowe8, Elie Karam9 and Denis Poddubnyy10, 1Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain / Spanish Federation of Spondyloarthritis Patient Associations (CEADE), Madrid, Spain, Seville, Spain, 2La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 3Sanatorio Julio Mendez, Buenos Aires, Argentina, 4Cardiff University, Cardiff, UK, Cardiff, United Kingdom, 5Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, Nicosia, Cyprus, 6Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, 7Mumbai Arthritis Clinic, Mumbai, India, Mumbai, India, 8Axial Spondyloarthritis International Federation, London, United Kingdom, 9Canadian Spondylitis Association (CSA), Toronto, Canada, Toronto, Canada, 10Charite-Universitatsmedizin Berlin, Berlin, Germany

    Background/Purpose: Severe pain in patients with axial spondyloarthritis (axSpA) can cause deterioration in their physical and mental health. The aim is to investigate factors associated…
  • Abstract Number: 0657 • ACR Convergence 2024

    Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis

    Jagan K L1, Augustine Jose2, Vishnupriya G1, Dellan S1, Dhanush S1, Samskruthi Reddy Tokala1, Bhavana Mashetty1, Chengappa Kavadichanda3, Sachith ganapathy1, Aishwarya Gopal4, Rithik Roshan1, Sareddy Sai vignesh Reddy1, Sonal Mehra5, Molly Thabah1 and Vir Singh Negi6, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 2Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, 4Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 5JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, 6AIIMS, Bilaspur, Puducherry, Puducherry, India

    Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
  • Abstract Number: 1025 • ACR Convergence 2024

    Gender Disparities in Disease Impact and Treatment Access for Spondyloarthropathies in Latin America: Insights from a Web Survey

    Sebastián Ibáñez1, María Dominga García1 and Natalia González2, 1Clínica Alemana de Santiago, Santiago, Region Metropolitana, Chile, 2Fundación Espondilitis Chile, Santiago, Region Metropolitana, Chile

    Background/Purpose: Previous studies have shown that female patients with spondyloarthritis (SpA) tend to experience a greater impact on their functionality, especially among women in Latin…
  • Abstract Number: 1337 • ACR Convergence 2024

    Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA

    Ali Malik1, Dennis Ang1, Adam Hall1, John Herion1 and Rupak Thapa2, 1Wake Forest University, Winston Salem, NC, 2Assistant Professor, Winston Salem, NC

    Background/Purpose: Gender and ethnic disparities in health care are well reported in the general medical literature.  Differences in symptom reporting or perceived health status can…
  • Abstract Number: 1397 • ACR Convergence 2024

    Temporal Trends in Early Rheumatoid Arthritis (ERA) Patients with Moderate to Severe Disease Activity: A Multicenter Cohort Study of Treatment Strategies and Outcomes in Chinese Patients in the Modern Era

    Yafang Deng1, Chen Yu2, Lin Qiao1, Nan Jiang1, Yanhong Wang3, Xinping Tian1, Qian Wang1, Mengtao Li4 and Xiaofeng Zeng1, 1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), 3Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 4Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China

    Background/Purpose: In the contemporary era, the continuous update of international rheumatoid arthritis (RA) guidelines has significantly impacted the diagnosis and management of RA patients in…
  • Abstract Number: 1681 • ACR Convergence 2024

    Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study

    Anna Zubrzycka-Sienkiewicz1, Kamilla Klama2, Martin Ullmann3, Corinne Petit-Frere3, Andras Illes3, Olga Menang3, Joëlle Monnet3 and Peter Baker3, 1Reumatika - Centrum Reumatologil", NZOZ, Warszawa, Poland, 2Solumed Centrum Medyczne, Poznań, Poland, 3Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland

    Background/Purpose: A therapy transition from the originator to a biosimilar offers significant advantages for patients by lowering medication costs and improving accessibility to treatments. MSB11456…
  • Abstract Number: 2026 • ACR Convergence 2024

    Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus

    Rebeca L. Polina-Lugo1, Aleydis Gonzalez Melendez1, Maria F. Elizondo-Benitez2, Andrea Guajardo Aldaco1, Annette Dominguez-Guerra3, Victoria P. Limas-Martínez1, Iris Jazmín Colunga Pedraza1, Dionicio Galarza-Delgado4, jose Ramon Azpiri-Lopez5, Rosa Icela Arvizu-Rivera1 and Jesus Cardenas-de la Garza6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 6Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    Background/Purpose: Increased disease activity by SLEDAI (Systemic Erythematosus Lupus Disease Activity Index) has been associated with higher cardiovascular risk (CVR) and atherosclerotic cardiovascular disease (ASCVD),…
  • Abstract Number: 2325 • ACR Convergence 2024

    Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration

    Stylianos Georgiadis1, Mikkel Ostergaard2, Jette Heberg3, Zohra Faizy Ahmadzay4, Brigitte Michelsen5, Simon Horskjær Rasmussen6, Mehrdad Kazemi6, Johan Karlsson Wallman7, Tor Olofsson8, Bente Glintborg9, Anne Gitte Loft10, Isabel Castrejón11, Ladislav Šenolt12, Michael J. Nissen13, Burkhard Moeller14, Jorge Garcia15, Filipe Barcelos16, Ziga Rotar17, Katja Perdan-Pikmajer17, Catalin Codreanu18, Corina Mogosan18, Karin Laas19, Sigrid Vorobjov20, Bjorn Gudbjornsson21, Gerdur Gröndal21, Dan Nordstrom22, Anna-Mari Hokkanen23, Pawel Mielnik24, Tore K. Kvien25, Gökçe Kenar26, Marleen Van De Sande27, Merete Hetland28 and Lykke Oernbjerg1, 1Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, 2Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 3Rigshospitalet Glostrup, København V, Denmark, 4Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, 5Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, 6Rigshospitalet Glostrup, Glostrup, Denmark, 7Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, 8Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, 9DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, 10Aarhus University Hospital and Aarhus University, Horsens, Denmark, 11Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, 12Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 13Geneva University Hospital, Geneva, Switzerland, 14Inselspital - University Hospital Bern, Bern, Switzerland, 15Clínica Médico Ourém, Ourém, Portugal, 16Universidade Nova de Lisboa, Instituto Português de Reumatologia and Hospital CUF Descobertas, Lisbon, Portugal, 17University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 18University of Medicine and Pharmacy, Bucharest, Romania, 19East-Tallinn Central Hospital, Tallinn, Estonia, 20National Institute for Health Development, Tallinn, Estonia, 21Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 22Helsinki University Hospital, Helsinki, Finland, 23Helsinki University and Helsinki University Hospital, Helsinki, Finland, 24Helse Førde, Førde, Norway, 25Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 26Dokuz Eylul University School of Medicine, Izmir, Turkey, 27Amsterdam Institute for Infection & Immunity and Reade and Amsterdam UMC, Amsterdam, Netherlands, 28Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark

    Background/Purpose: Several predictors of treatment response to tumour necrosis factor inhibitors (TNFi) in routine care have been reported in psoriatic arthritis (PsA). However, data on…
  • Abstract Number: 2481 • ACR Convergence 2024

    General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Rula A. Hajj-Ali1, Duvuru Geetha2, Raashid Luqmani3, Christian Pagnoux4, Darcy Trimpe5, David Jayne6 and Peter Merkel7, and ADVOCATE Study Group, 1Cleveland Clinic, Cleveland, OH, 2Johns Hopkins University, Baltimore, MD, 3University of Oxford, Abingdon, United Kingdom, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Amgen Inc., Thousand Oaks, CA, 6University of Cambridge, Cambridge, United Kingdom, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The most common types of ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), can affect a range of organs, including the kidneys,…
  • Abstract Number: 0412 • ACR Convergence 2024

    Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center

    Anna Sutton1, Erin Balay-Dustrude1, Beth A Mueller1 and Susan Shenoi2, 1University of Washington, Seattle, WA, 2Seattle Children's Hospital and Research Center, Mercer Island, WA, WA

    Background/Purpose: In clinical trials, biologic disease-modifying antirheumatic drugs (bDMARDs) for juvenile idiopathic arthritis (JIA) have demonstrated good efficacy. However, less is known about the impact…
  • Abstract Number: 0569 • ACR Convergence 2024

    The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort

    Augusta Ortolan1, Desiree van der Heijde2, Laure Gossec3 and Sofia Ramiro4, 1Policlinico Universitario Agostino Gemelli IRCSS, Rome, Lazio, Italy, 2Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 3Sorbonne Université, Paris, France, 4Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Health-related quality of life (HRQoL) in axSpA is considered an overarching outcome, with other disease outcomes contributing to it [1]. To validate a previously…
  • Abstract Number: 0660 • ACR Convergence 2024

    Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis

    Shivani Garg1, Brad Rovin2, Brad Astor1, Tripti Singh1, Lexie Kolton1, Callie Saric1, S. Sam Lim3 and Christie Bartels4, 1University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 2The Ohio State University, Columbus, OH, 3Emory University, Atlanta, GA, 4University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
  • Abstract Number: 1060 • ACR Convergence 2024

    Therapeutic Hydroxychloroquine Blood Levels Predict Lower Mean Frequency of Recurrent Acute Care Utilization in Lupus

    Shivani Garg1, Giancarlo Valiente2, Callie Saric1, Betty Chewning3 and Christie Bartels4, 1University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 2University of Wisconsin, School of Medicine and Public Health, Madison, 3University of Wisconsin, School of Pharmacy, Madison, 4University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is highly prevalent in lupus (or SLE) and two-fold higher in patients of Black race or Hispanic ethnicity. While HCQ…
  • 1
  • 2
  • 3
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology